Fight disinformation. Get a daily recap of the facts that matter. Sign up for the free Mother Jones newsletter.

In our last episode of Health Update, my M-protein level was starting to rise, indicating that the Revlimid was losing effectiveness and the multiple myeloma was staging a comeback. This is normal and expected after two years. When it got above 1.0, it would be time to switch to a second-line treatment. In the end, I got nearly three years out of the Revlimid, but the time has now come to move on:

The new treatment will consist of an oral version of my old friend Velcade teamed up with Darzalex, a monoclonal antibody that’s one of the slew of new treatments that have been approved over the past few years. I will also once again be taking the evil dex, a sleep killer marketed as a corticosteroid. During my last round of dex, I used my treatment nights to write a 40-page tutorial on special and general relativity. I can’t really say why I did that, but I’m sure it would have been a publishing sensation if I had ever published it.

Anyway, the new treatment will start in a week or so. It’s once a week for two months, then once every two weeks for two months, and then once a month. The total length of time depends on how I respond. Once the M-proteins are back under control, I’ll begin a maintenance routine which will hopefully last a couple of years. Keep your fingers crossed.

We Recommend


Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.


Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.